Biography
Biography, professional timeline and areas of expertise of pharmacist Stasinos Chr. Sikalias.
SIKALIAS PHARMACY · IN MY OWN WORDS
The values behind my pharmacy practice.
In this short film, I describe our family pharmacy’s continuity, compounding practice and team. A personal introduction to the values that guide my day-to-day work.
Watch at Sikalias PharmacyGreek audio · English and Greek subtitles
Professional summary
Stasinos Chr. Sikalias is a pharmacist, leading Sikalias Pharmacy since 1998 and Managing Director & R&D Manager of Sikalias Pharmaceutical Laboratories. His work bridges community practice, evidence-based compounding, pharmaceutical care, formulation science and health-product development.
Timeline
- 1967: Christos Sikalias establishes the family pharmacy in Peristeri; Rena Sikalia later continues its course.
- 1995: Pharmacy degree, National and Kapodistrian University of Athens.
- 1997–1999: Postgraduate studies in Biopharmaceutics–Pharmacokinetics.
- 1998: Stasinos Chr. Sikalias takes the family pharmacy forward.
- From 2000: Systematic specialisation in pharmaceutical compounding and evidence-based formulation.
- 2003: Development of the Kallio natural dermocosmetic activity.
- 2012: Laboratory and product-development activity that evolved into Sikalias Pharmaceutical Laboratories.
- 2015: Coordinator of the Pharmacy Laboratory Committee of IDEEAF, with Professor Paraskevas Dallas as head.
- 2016: PFS assigns the Committee the preparation of a quality-assurance system and Greek compounding formulary, under Board decision 5/16.5.2016, communicated on 27 June 2016.
- 2017: Major upgrade of production and R&D infrastructure.
- 2025–2026: A two-site development and manufacturing platform in Peristeri: GMP-certified Site 0 / EOF-authorized Site 1. Current site-specific documentation is provided by the Laboratories’ QA team. Quality documentation
Areas of expertise
SIKALIAS PHARMACEUTICAL LABORATORIES
Turn a scientific question into a development brief.
Discuss formulation R&D, technology transfer, CMO / CDMO or European nearshoring with the Laboratories. Start with a non-confidential outline of your dosage form, development stage, target market and volume.